Where Can You Get a Long-Acting Naltrexone Implant? U.S. Availability vs Treatment in The Bahamas
No opioid-free waiting window before starting treatment at DeBinge When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
If you are searching for a “naltrexone implant clinic near me” in the United States, there is an important distinction to understand first: naltrexone implants are not FDA-approved for clinical use in the United States. U.S. patients can access FDA-approved forms of naltrexone, including appropriate oral formulations and extended-release injectable naltrexone, through qualified U.S. healthcare providers. Implant treatment is a different form of sustained-release naltrexone and may be available in other countries under different regulatory systems.
DeBinge implant-based treatment takes place in Nassau, The Bahamas. The process begins with consultation and medical assessment before treatment travel is arranged. Travelling to The Bahamas should only be considered when the clinical team determines that the proposed treatment and timing are medically appropriate.
Naltrexone implant formulations are not FDA-approved in the United States. DeBinge does not operate a naltrexone implant clinic in Miami, Atlanta, Charlotte or elsewhere in the U.S. Implant-based treatment offered through DeBinge takes place in Nassau, The Bahamas.
What Does “Naltrexone Treatment Near Me” Actually Mean?
Someone searching for long-acting naltrexone treatment may actually be looking for one of two very different things. Understanding the distinction can prevent confusion about availability and FDA approval.
1. FDA-Approved Naltrexone Treatment in the U.S.
A U.S. addiction physician, psychiatrist, primary-care clinician or other appropriately qualified provider may be able to discuss oral naltrexone or extended-release injectable naltrexone. These options do not require international travel.
2. Sustained-Release Implant Treatment Outside the U.S.
A patient specifically seeking a subcutaneous long-acting implant may need to consider treatment in a jurisdiction where the particular implant is legally available and clinically provided. DeBinge implant-based treatment takes place in Nassau, The Bahamas.
Before comparing locations, it is worth understanding the medication itself. Our main educational guide explains how long-acting naltrexone implants work, what the evidence shows, safety considerations and regulatory differences.
What Naltrexone Treatment Is Available in the U.S.?
Naltrexone itself is an established medication used in treatment for alcohol use disorder and opioid use disorder. However, approval of the medication does not mean that every delivery system containing naltrexone is FDA-approved.
For U.S. patients, the principal naltrexone formulations to discuss with a qualified healthcare professional are oral naltrexone and extended-release injectable naltrexone.
Oral Naltrexone
Oral naltrexone is taken according to a prescribed schedule. It avoids a procedure and allows treatment to be changed or discontinued comparatively easily, but effectiveness depends partly on medication adherence.
If the person stops taking the tablets, antagonist coverage declines. For this reason, adherence has historically been an important limitation of oral naltrexone, particularly in opioid use disorder.
Extended-Release Injectable Naltrexone
Extended-release injectable naltrexone, widely known by the U.S. brand name Vivitrol®, is administered by intramuscular injection approximately once every four weeks.
It reduces the need to make a daily medication decision while avoiding the surgical placement required for an implant. It is FDA-approved for appropriate treatment of alcohol dependence and prevention of relapse to opioid dependence following opioid detoxification.
SAMHSA identifies naltrexone as one of the medication options used in treatment for opioid and alcohol use disorders. NIDA and FDA also identify naltrexone alongside buprenorphine and methadone among FDA-approved medication approaches for opioid use disorder.
People deciding between available formulations can read our comparison of oral naltrexone, extended-release injectable naltrexone and implant treatment.
What Is Different About a Long-Acting Naltrexone Implant?
A naltrexone implant is designed to release naltrexone gradually after a sustained-release formulation is placed beneath the skin. Published research has investigated different implant formulations with different doses, materials and durations.
The principal practical difference is adherence. A tablet normally requires repeated medication decisions. An injection reduces those decisions for approximately one month. An implant may provide medication exposure over a longer period depending on the particular formulation.
That does not mean every implant is equivalent. The phrase “naltrexone implant” describes a category rather than one standardized global product. Anyone considering treatment should ask what exact formulation is being offered and what clinical or pharmacokinetic evidence applies to that product.
A 2012 randomized trial involving 306 recently detoxified opioid-dependent participants, for example, investigated a specific 1,000 mg naltrexone implant against oral naltrexone and placebo in Russia. The results were relevant to that formulation and treatment setting. They do not establish that every implant has the same duration, effectiveness or safety profile.
Our detailed long-acting naltrexone implant knowledge hub examines these evidence limitations in more detail.
Why Can Treatment Availability Differ Between Countries?
Medicines and drug-delivery systems are regulated nationally. A medication may have regulatory authorization in one formulation or jurisdiction without having equivalent authorization in another.
In the United States, FDA-approved medication options for opioid use disorder include buprenorphine, methadone and naltrexone. Appropriate oral naltrexone formulations and extended-release injectable naltrexone are available. Naltrexone implants are not FDA-approved for clinical use in the United States.
This is important because websites sometimes blur three separate statements:
- naltrexone is an established medication;
- some formulations of naltrexone are FDA-approved;
- a particular naltrexone implant is FDA-approved.
The first two can be true without the third being true.
Patients considering treatment outside their home country should ask which authority regulates the treatment where it will actually occur, what permissions apply to the product and clinical service, and whether the evidence presented relates to the specific formulation being used.
Where Does DeBinge Provide Implant-Based Treatment?
DeBinge implant-based treatment is provided in Sandyport, Nassau, The Bahamas. U.S. patients can begin the information-gathering, consultation and assessment process while still at home, but the implant procedure itself is not performed in the United States.
You can see the treatment setting and broader approach to care on the DeBinge clinic page for Sandyport, Nassau.
Location should never be the first clinical question. Before flights or accommodation are booked, the more important issue is whether the proposed treatment is medically suitable and whether the person is stable enough to travel.
Looking for implant-based treatment from the United States?
The first stage should be discussion and assessment rather than booking a flight. Treatment planning depends on substance use, medications, medical history, withdrawal risk and the individual’s goals.
Explore the Nassau Treatment Setting Questions for Comparing Implant ProgramsWhy Might Someone Travel for Naltrexone Implant Treatment?
There are several reasons a person may investigate treatment outside the United States. The most obvious is availability: someone who specifically wants to discuss a sustained-release implant cannot obtain an FDA-approved naltrexone implant from a U.S. clinic because no such implant has FDA approval.
Other people may value privacy, a temporary change of environment, structured medical preparation or the ability to begin recovery away from locations and routines strongly associated with substance use.
These factors may influence where someone chooses to receive care, but none of them establishes that international implant treatment is medically preferable to local treatment.
For some patients, remaining close to home and using oral naltrexone, extended-release injectable naltrexone, buprenorphine, methadone or another evidence-based treatment may be more appropriate. For others, discussing an implant abroad may form part of shared decision-making.
The Bahamas can provide a different environment, but beaches, privacy and distance from everyday life cannot treat addiction by themselves. Medical care, appropriate medication, counselling, behavioural change and a plan for returning home remain central.
Medical Preparation Should Come Before the Flight
A patient should not assume that arriving in Nassau automatically means an implant can be placed. Naltrexone suitability requires individual assessment, and opioid dependence creates a particularly important preparation issue.
Current opioid dependence
Naltrexone is an opioid antagonist. If it is introduced while significant opioid physical dependence remains, it can precipitate abrupt and potentially severe withdrawal.
FDA prescribing information for extended-release injectable naltrexone recommends an opioid-free period before administration and warns that precipitated withdrawal can be severe enough to require hospitalization. The label provides specific guidance for the FDA-approved injectable formulation, but those numbers should not be turned into a universal detox schedule for every implant patient.
Fentanyl exposure, methadone, buprenorphine, long-acting prescription opioids, frequency of use, uncertain street-drug composition and individual physiology can all affect clinical planning. Readiness needs to be assessed rather than assumed from a calendar.
Alcohol dependence
Naltrexone is also used in alcohol use disorder, but naltrexone itself does not manage dangerous acute alcohol withdrawal. A person who may be physically dependent on alcohol should not abruptly stop drinking solely to prepare for an international journey without appropriate medical advice.
Alcohol withdrawal can be medically serious and, in some cases, life-threatening. A clinician should assess withdrawal risk and determine what preparation is required before travel.
Medical stability
International treatment planning should also consider other medications, liver function where clinically indicated, significant medical conditions, psychiatric needs, previous withdrawal complications, wound-healing considerations and the possibility of needing opioid pain treatment.
Severe withdrawal, intoxication, dehydration, confusion, seizures, breathing difficulties or other urgent symptoms require appropriate local medical assessment. Convenience of travel should never override immediate medical safety.
A More Responsible Way to Plan International Treatment
Start With a Private Consultation
Discuss the substance involved, current use, medications, medical history, previous treatment, recovery goals and why a long-acting formulation is being considered.
Establish Whether Further Assessment Is Needed
Clinical history, laboratory testing, toxicology or other assessments may be required depending on the individual circumstances.
Address Withdrawal and Stabilisation
If opioid or alcohol physical dependence is present, the medical team should determine how the person can be prepared safely. There should not be a one-size-fits-all promise that everyone follows an identical detox schedule.
Confirm Medical Readiness to Travel
Flights should not be treated as the starting point of clinical planning. Travel should fit the medical plan rather than forcing the medical plan to fit a ticket.
Final Assessment Before Implantation
Suitability should be reassessed before the procedure. New opioid use, illness, medication changes or other developments may affect whether treatment can proceed.
Plan the Return Home Before Leaving Home
Counselling, local medical contacts, overdose planning, wound care and longer-term recovery support should be considered before the patient returns to the United States.
Confidentiality and Private International Treatment
Privacy can be an important factor for people seeking addiction treatment, particularly professionals, business owners, public-facing individuals and families who do not want unnecessary disclosure of sensitive health information.
However, privacy should not mean isolation from necessary healthcare. A responsible confidentiality plan should preserve discretion while still allowing essential medical information to be communicated when needed for safety and continuity of care.
Patients should ask how medical information is handled, who has access to records, how communication takes place, what information might be necessary in an emergency and how relevant information can be shared with the patient’s own clinician when authorized.
Learn more about private and confidential naltrexone implant treatment planning.
What Should You Verify About Any Naltrexone Implant Clinic?
A polished website or persuasive testimonial should not replace clinical due diligence. Before travelling to any country for implant treatment, patients should know who is responsible for their medical care and what exact treatment is being proposed.
Clinician Qualifications
- Who conducts the medical assessment?
- Who performs or supervises the procedure?
- What professional qualifications do they hold?
- Where are they licensed or registered?
- What addiction-treatment experience do they have?
The Exact Implant
- What is the formulation and dose?
- Who manufactures it?
- What is its release profile?
- What clinical studies investigated that formulation?
- What is known about local procedure complications?
Medical Preparation
- How is current opioid dependence assessed?
- How is readiness for naltrexone determined?
- What happens if the patient is not ready on arrival?
- How are alcohol-withdrawal risks assessed?
Aftercare
- Who manages follow-up after the procedure?
- What counselling is available?
- Who should be contacted about an implant-site problem?
- What happens when medication exposure declines?
Our guide to comparing naltrexone implant programs provides a structured set of questions patients and families can use when reviewing different providers.
Follow-Up After Returning to the United States
An international procedure should not create a gap in healthcare once the patient boards the flight home.
A useful return-home plan can include counselling, a local physician or addiction specialist where appropriate, clear wound-care instructions, medication information, emergency information about opioid receptor blockade and an understanding of who to contact if a problem develops.
Patients should also understand that long-acting naltrexone affects future opioid pain treatment. Doctors, dentists, emergency clinicians and surgeons may need to know that naltrexone is active when making decisions about analgesia.
For someone with previous opioid use disorder, overdose safety remains important. Opioid tolerance can fall during abstinence, and attempting to overcome naltrexone blockade with high opioid doses can be dangerous. When medication concentrations eventually decline, returning to a previously tolerated opioid dose can also present substantial overdose risk.
Patients and families should discuss naloxone availability and overdose response with a clinician rather than assuming an implant guarantees protection.
Warning Signs When Comparing Implant Treatment Advertising
Be cautious when a provider or marketer:
- claims a naltrexone implant is FDA-approved in the United States;
- uses FDA approval of oral or injectable naltrexone to imply FDA approval of an implant;
- guarantees that treatment will eliminate cravings;
- guarantees permanent abstinence or recovery;
- claims an implant makes opioid overdose impossible;
- promises the same detox timetable for every patient;
- does not identify the specific implant formulation being used;
- quotes research on another formulation as though it automatically proves the performance of its own implant;
- discourages questions about clinician credentials or product regulation;
- focuses on travel, luxury or scenery while providing little information about medical assessment and follow-up;
- does not explain alternatives such as oral naltrexone, injectable naltrexone, buprenorphine or methadone where clinically relevant;
- suggests counselling is unnecessary because the medication will “solve” addiction.
Good treatment communication should make uncertainty understandable rather than hiding it. Patients should know what is established, what is formulation-specific and which decisions still require individual clinical assessment.
15 Questions to Ask Any Long-Acting Naltrexone Provider
- What exact naltrexone formulation are you proposing?
- What evidence specifically supports that formulation?
- What is its regulatory status where treatment will take place?
- Who will assess whether I am medically suitable?
- Who performs or supervises the procedure?
- What professional qualifications and registrations do those clinicians hold?
- If I currently use opioids, how will you determine when it is safe to administer naltrexone?
- What happens if I am not sufficiently prepared when I arrive?
- What procedure-related complications should I know about?
- How long has this specific formulation been shown to maintain clinically relevant exposure?
- Can the implant be removed, and under what circumstances would removal be considered?
- What should I do if I need surgery or opioid pain treatment?
- What counselling and behavioural treatment accompany the medication?
- What follow-up is available after I return home?
- What is the plan for the period when the implant’s medication release declines?
Should You Discuss Local Naltrexone Treatment or International Implant Treatment With a Clinician?
This nine-question tool does not determine whether you should travel, diagnose a substance use disorder or recommend a naltrexone implant. It identifies topics to discuss with a qualified clinician before deciding where treatment should take place.
Your responses are calculated inside your browser and are not submitted to DeBinge.
Your Discussion Priorities
Your answers identify subjects that may deserve more attention before you decide whether to continue local treatment discussions or investigate an international implant program. They are not a recommendation to travel.
Naltrexone Implant Clinic and Bahamas Treatment FAQ
Can I get a naltrexone implant in the United States?
Naltrexone implants are not FDA-approved for clinical use in the United States. U.S. patients can discuss FDA-approved naltrexone formulations, including appropriate oral naltrexone and extended-release injectable naltrexone, with qualified U.S. healthcare providers.
Is there an FDA-approved long-acting naltrexone implant clinic near me?
No U.S. clinic can provide an FDA-approved naltrexone implant because no naltrexone implant formulation is currently FDA-approved for clinical use in the United States. A clinic may offer FDA-approved extended-release injectable naltrexone, which is a different formulation.
Where does DeBinge provide naltrexone implant treatment?
DeBinge implant-based treatment takes place in Sandyport, Nassau, The Bahamas. DeBinge does not operate implant treatment clinics in Miami, Atlanta, Charlotte or elsewhere in the United States.
Can I have a consultation while I am still in the United States?
The initial discussion and treatment planning can begin before travel. This allows medical history, substance use, medications, treatment goals and potential preparation requirements to be considered before arrangements are finalized.
Should I detox before flying to The Bahamas?
Do not create your own detox schedule solely for the purpose of reaching an implant appointment. If opioid or alcohol physical dependence may be present, withdrawal and travel need individualized medical planning. Starting naltrexone while opioid dependence remains can precipitate severe withdrawal, while abrupt alcohol withdrawal can also be medically dangerous for some people.
Is Vivitrol the same as a naltrexone implant?
No. Vivitrol is an FDA-approved extended-release intramuscular naltrexone injection generally administered every four weeks. A naltrexone implant is placed subcutaneously and uses a different drug-delivery system. Implant formulations are not FDA-approved for clinical use in the United States.
Why would someone consider an implant instead of oral naltrexone?
A long-acting formulation can reduce dependence on daily medication adherence. However, suitability depends on the patient’s goals, substance-use history, medical circumstances and alternatives. Longer medication exposure is not automatically better for every person.
Does going abroad mean the treatment is experimental?
Not necessarily. Regulatory authorization differs between countries, and different implant formulations have been studied in peer-reviewed research. However, evidence and regulatory status should be evaluated for the exact formulation and jurisdiction involved. U.S. FDA approval should never be implied where it does not exist.
Is treatment in The Bahamas confidential?
Patients can ask DeBinge about its privacy and information-handling procedures before treatment. Confidentiality should be balanced with safe continuity of care, particularly when medical information needs to be available to clinicians involved in treatment or emergencies.
What happens after I return to the United States?
A return-home plan should address counselling, medical follow-up where required, wound care, emergency information about naltrexone, overdose safety and the longer-term recovery plan. Long-acting medication does not replace continuing recovery support.
Does a naltrexone implant guarantee that I cannot relapse?
No. Naltrexone can block or reduce opioid effects while sufficient antagonist activity is present and may support treatment for alcohol use disorder, but no implant guarantees abstinence, eliminates every craving or guarantees recovery.
Can an implant guarantee protection from opioid overdose?
No. Attempting to overpower opioid receptor blockade with large opioid quantities can be extremely dangerous. Opioid tolerance can also fall during abstinence, increasing risk when antagonist coverage declines or treatment ends. Naloxone and overdose planning remain important where opioid exposure is possible.
Sources and Further Reading
U.S. Food and Drug Administration
FDA information on medications for opioid use disorder identifies buprenorphine, methadone and naltrexone as FDA-approved medication approaches for OUD.
SAMHSA
SAMHSA provides clinical and patient information on oral and extended-release injectable naltrexone and publishes TIP 63 guidance on medications for opioid use disorder.
NIDA
The National Institute on Drug Abuse provides information about methadone, buprenorphine and naltrexone as medications used for opioid use disorder and reports research into extended-release naltrexone initiation.
ASAM
The American Society of Addiction Medicine National Practice Guideline addresses opioid agonist, partial-agonist and antagonist treatment, including extended-release injectable naltrexone for appropriately selected patients who are no longer physically dependent on opioids.
FDA-Approved Injectable Naltrexone Label
Current prescribing information for extended-release injectable naltrexone includes warnings about precipitated opioid withdrawal, vulnerability to opioid overdose and attempts to overcome opioid blockade.
DailyMed: Extended-Release Naltrexone Prescribing Information
Peer-Reviewed Implant Research
Krupitsky E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry. 2012;69(9).
Evidence and regulatory information checked for this educational page in September 2026. Regulations, product availability and prescribing information may change. Patients should confirm current information with their clinician and the relevant regulatory authority.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This page has been prepared as an educational resource and is awaiting formal clinical approval. Until that review is completed, it should not be described as medically reviewed.
View Dr Fergus Law’s professional profile and background
Review status: Pending clinical approvalAvailability Information Is Not a Treatment Recommendation
This page explains the difference between FDA-approved naltrexone options available in the United States and international naltrexone implant treatment. It does not determine whether a naltrexone implant, injectable naltrexone, oral naltrexone, methadone, buprenorphine or another treatment is appropriate for a particular person.
Do not stop opioids or alcohol, change prescribed medication, begin naltrexone or travel internationally for treatment based only on information on this page. Treatment decisions require individual medical assessment.
Severe withdrawal, seizures, loss of consciousness, abnormal breathing, suspected overdose, severe intoxication or another medical emergency requires immediate local emergency assistance.